Yasuhiro Izumiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasuhiro Izumiya has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
Shinsuke Hanatani
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
31 shared publicationsEiichiro Yamamoto
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
24 shared publicationsKenichi Tsujita
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
24 shared publicationsHisao Ogawa
National Cerebral and Cardiovascular Center, Suita, Japan
23 shared publicationsSatoshi Araki
Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University
22 shared publicationsSeiji Takashio
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
18 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- p. 1-11
Cardiac amyloidosis: what every interventional cardiologist should know
Cardiac amyloidosis (CA) is increasingly encountered by interventional cardiologists during the evaluation of chest pain, myocardial injury, coronary artery disease, atrial arrhythmias, and aortic stenosis. Its recognition can be challenging because amyloid cardiomyopathy often coexists with common coronary, valvular, and arrhythmic conditions. A key diagnostic clue is discordance: the apparent coronary, valvular, or hemodynamic abnormality does not fully explain the patient’s symptoms, myocardial phenotype, low-flow physiology, or persistent high-sensitivity cardiac troponin elevation. This review focuses on clinical situations in which interventional cardiologists should suspect CA. We discuss myocardial ischemia and coronary microvascular dysfunction caused by intramural vascular amyloid deposition, extravascular compression, and impaired vasodilator reserve; atrial arrhythmias and catheter ablation; the frequent coexistence of transthyretin cardiac amyloidosis (ATTR-CM) with aortic stenosis in patients undergoing transcatheter aortic valve implantation; and the complementary roles of echocardiography, cardiac computed tomography, cardiovascular magnetic resonance, bone-avid tracer scintigraphy, and invasive hemodynamic assessment. We also propose a practical cath-lab approach that integrates readily available clinical information, recognizes persistent or disproportionate myocardial injury as a diagnostic red flag, promptly distinguishes light-chain from ATTR amyloidosis, and preserves appropriate treatment of coexisting coronary or valvular disease. For the interventional cardiologist, the central principle is simple: when the lesion does not fully explain the patient, look beyond the lesion.
- 8 October 2026
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- p. 1-11
Open AccessCardiac amyloidosis: what every interventional cardiologist should know
Cardiac amyloidosis (CA) is increasingly encountered by interventional cardiologists during the evaluation of chest pain, myocardial injury, coronary artery disease, atrial arrhythmias, and aortic stenosis. Its recognition can be challenging because amyloid cardiomyopathy often coexists with common coronary, valvular, and arrhythmic conditions. A key diagnostic clue is discordance: the apparent coronary, valvular, or hemodynamic abnormality does not fully explain the patient’s symptoms, myocardial phenotype, low-flow physiology, or persistent high-sensitivity cardiac troponin elevation. This review focuses on clinical situations in which interventional cardiologists should suspect CA. We discuss myocardial ischemia and coronary microvascular dysfunction caused by intramural vascular amyloid deposition, extravascular compression, and impaired vasodilator reserve; atrial arrhythmias and catheter ablation; the frequent coexistence of transthyretin cardiac amyloidosis (ATTR-CM) with aortic stenosis in patients undergoing transcatheter aortic valve implantation; and the complementary roles of echocardiography, cardiac computed tomography, cardiovascular magnetic resonance, bone-avid tracer scintigraphy, and invasive hemodynamic assessment. We also propose a practical cath-lab approach that integrates readily available clinical information, recognizes persistent or disproportionate myocardial injury as a diagnostic red flag, promptly distinguishes light-chain from ATTR amyloidosis, and preserves appropriate treatment of coexisting coronary or valvular disease. For the interventional cardiologist, the central principle is simple: when the lesion does not fully explain the patient, look beyond the lesion.
- Open Access
A First-Visit Clinical Score to Distinguish Immunoglobulin Light-Chain from Wild-Type Transthyretin Cardiac Amyloidosis: Derivation and Internal Validation
Background: Delayed diagnosis of immunoglobulin light-chain cardiac amyloidosis (AL-CA) worsens prognosis, partly because AL-CA and wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) are difficult to distinguish at the initial cardiology visit. We developed and validated a practical score to triage AL-CA from ATTRwt-CA. Methods: We retrospectively analyzed 541 consecutive patients with cardiac amyloidosis (91 AL-CA, 450 ATTRwt-CA) at our institution's amyloidosis center, randomly divided into derivation (n=378) and validation (n=163) cohorts. Candidate first-visit variables underwent LASSO selection after multiple imputation, with estimates pooled by Rubin's rules. Performance was assessed by bootstrap validation, calibration, and decision curve analysis. The model was converted into a simplified point-based score. Results: Seven variables were retained: age, absence of atrial fibrillation, absence of carpal tunnel syndrome, low serum albumin, proteinuria (≥1+), low voltage, and thinner left ventricular posterior wall thickness. Areas under the curve (AUC) were 0.97 in the derivation cohort and 0.99 in the validation cohort; the bootstrap optimism-corrected AUC was 0.96. The model provided net benefit across threshold probabilities of 0.01-0.50. Risk tiering categorized the validation cohort into low (0-5 points; AL-CA 0%), intermediate (6?9 points; 26%), and high (10-13 points; 95%) probability groups. Discrimination remained high for AL-CA versus monoclonal protein-positive ATTRwt-CA at a cutoff of ≥8 points (AUC 0.90). Adding this score to monoclonal protein testing significantly improved diagnostic performance compared with monoclonal protein testing alone. Conclusions: This simple first-visit score may help cardiologists rapidly triage suspected AL-CA and prioritize urgent hematology referral and subtype-specific confirmatory testing.
Open AccessA First-Visit Clinical Score to Distinguish Immunoglobulin Light-Chain from Wild-Type Transthyretin Cardiac Amyloidosis: Derivation and Internal Validation
Background: Delayed diagnosis of immunoglobulin light-chain cardiac amyloidosis (AL-CA) worsens prognosis, partly because AL-CA and wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) are difficult to distinguish at the initial cardiology visit. We developed and validated a practical score to triage AL-CA from ATTRwt-CA. Methods: We retrospectively analyzed 541 consecutive patients with cardiac amyloidosis (91 AL-CA, 450 ATTRwt-CA) at our institution's amyloidosis center, randomly divided into derivation (n=378) and validation (n=163) cohorts. Candidate first-visit variables underwent LASSO selection after multiple imputation, with estimates pooled by Rubin's rules. Performance was assessed by bootstrap validation, calibration, and decision curve analysis. The model was converted into a simplified point-based score. Results: Seven variables were retained: age, absence of atrial fibrillation, absence of carpal tunnel syndrome, low serum albumin, proteinuria (≥1+), low voltage, and thinner left ventricular posterior wall thickness. Areas under the curve (AUC) were 0.97 in the derivation cohort and 0.99 in the validation cohort; the bootstrap optimism-corrected AUC was 0.96. The model provided net benefit across threshold probabilities of 0.01-0.50. Risk tiering categorized the validation cohort into low (0-5 points; AL-CA 0%), intermediate (6?9 points; 26%), and high (10-13 points; 95%) probability groups. Discrimination remained high for AL-CA versus monoclonal protein-positive ATTRwt-CA at a cutoff of ≥8 points (AUC 0.90). Adding this score to monoclonal protein testing significantly improved diagnostic performance compared with monoclonal protein testing alone. Conclusions: This simple first-visit score may help cardiologists rapidly triage suspected AL-CA and prioritize urgent hematology referral and subtype-specific confirmatory testing.
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e042486
Right Atrial Function as a Novel Predictor for New‐Onset Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
Background: Left atrial functional parameters are established predictors of atrial fibrillation (AF), but the role of right atrial (RA) function, particularly RA peak longitudinal strain (LS), in transthyretin amyloid cardiomyopathy (ATTR‐CM) remains unclear. This study aimed to investigate the relationship between RA function and AF onset in ATTR‐CM. Methods: The derivation cohort comprised 143 patients with ATTR‐CM without prior atrial arrhythmias at Kumamoto University Hospital. Association between baseline parameters and new‐onset AF during the follow‐up period was analyzed using Cox regression models. Discrimination was assessed using time‐dependent receiver operating characteristic analysis at 24 months. Results: During follow‐up (median, 30 months), 42 patients (29%) developed new‐onset AF. Lower RA peak LS was independently associated with incident AF and showed moderate discrimination (time‐dependent area under the curve, 0.72); the optimal cutoff at 24 months was 17.2%. Patients with RA peak LS <17.2% had significantly lower AF‐free survival. A novel risk score integrating RA and left atrial peak LS and LA volume index effectively stratified AF risk. External validation in an independent cohort of 81 patients from Oita and Miyazaki University Hospitals confirmed consistent associations between lower RA peak LS and higher AF incidence, supporting the reproducibility of the findings. Conclusions: RA peak LS is a novel, robust predictor of new‐onset AF in ATTR‐CM and provides additional information alongside established clinical and left atrial parameters. Incorporating RA functional assessment may improve risk stratification and guide early interventions in high‐risk patients.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e042486
Open AccessRight Atrial Function as a Novel Predictor for New‐Onset Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
Background: Left atrial functional parameters are established predictors of atrial fibrillation (AF), but the role of right atrial (RA) function, particularly RA peak longitudinal strain (LS), in transthyretin amyloid cardiomyopathy (ATTR‐CM) remains unclear. This study aimed to investigate the relationship between RA function and AF onset in ATTR‐CM. Methods: The derivation cohort comprised 143 patients with ATTR‐CM without prior atrial arrhythmias at Kumamoto University Hospital. Association between baseline parameters and new‐onset AF during the follow‐up period was analyzed using Cox regression models. Discrimination was assessed using time‐dependent receiver operating characteristic analysis at 24 months. Results: During follow‐up (median, 30 months), 42 patients (29%) developed new‐onset AF. Lower RA peak LS was independently associated with incident AF and showed moderate discrimination (time‐dependent area under the curve, 0.72); the optimal cutoff at 24 months was 17.2%. Patients with RA peak LS <17.2% had significantly lower AF‐free survival. A novel risk score integrating RA and left atrial peak LS and LA volume index effectively stratified AF risk. External validation in an independent cohort of 81 patients from Oita and Miyazaki University Hospitals confirmed consistent associations between lower RA peak LS and higher AF incidence, supporting the reproducibility of the findings. Conclusions: RA peak LS is a novel, robust predictor of new‐onset AF in ATTR‐CM and provides additional information alongside established clinical and left atrial parameters. Incorporating RA functional assessment may improve risk stratification and guide early interventions in high‐risk patients.
- Open Access
- 24 February 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (14) , 107025
Paradoxical Pulmonary Congestion After Mavacamten in Obstructive HCM
- 24 February 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (14) , 107025
Open AccessParadoxical Pulmonary Congestion After Mavacamten in Obstructive HCM
- Open Access
- 23 January 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (2) , 217-227
Non-Ischemic Late Iodine Enhancement on Cardiac Computed Tomography ― Prevalence and Prognostic Significance ―
Background: Cardiac computed tomography (CCT) not only evaluates coronary artery disease but also characterizes myocardial features through late iodine enhancement (LIE). This study evaluated the clinical characteristics and prognostic significance of incidentally detected non-ischemic LIE patterns in patients undergoing CCT for coronary artery evaluation.Methods and Results: We retrospectively analyzed 465 patients who underwent CCT between January 2020 and December 2021. The primary outcome was all-cause death, and the secondary outcome was cardiovascular events, defined as cardiac death and unplanned cardiovascular hospitalization. Cox hazard analysis was performed to identify parameters significantly associated with the outcomes. After excluding patients with non-ischemic cardiomyopathy diagnosed before and after undergoing CCT, coronary stenosis and previous revascularization, 57 patients had non-ischemic LIE and 408 showed no LIE. Compared with patients without LIE, non-ischemic LIE was significantly associated with increased high-sensitivity cardiac troponin T and B-type natriuretic peptide levels, left ventricular (LV) diastolic diameter, LV thickness, and impaired LV ejection fraction. The cumulative incidence of cardiovascular events was significantly higher in patients with non-ischemic LIE than in those without LIE (log-rank P=0.024). In the Cox multivariable analysis, non-ischemic LIE was associated with cardiovascular events (hazard ratio 7.01; 95% confidence interval 1.09–42.2; P=0.041).Conclusions: CCT may provide prognostic significance through the assessment of myocardial properties.
- 23 January 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (2) , 217-227
Open AccessNon-Ischemic Late Iodine Enhancement on Cardiac Computed Tomography ― Prevalence and Prognostic Significance ―
Background: Cardiac computed tomography (CCT) not only evaluates coronary artery disease but also characterizes myocardial features through late iodine enhancement (LIE). This study evaluated the clinical characteristics and prognostic significance of incidentally detected non-ischemic LIE patterns in patients undergoing CCT for coronary artery evaluation.Methods and Results: We retrospectively analyzed 465 patients who underwent CCT between January 2020 and December 2021. The primary outcome was all-cause death, and the secondary outcome was cardiovascular events, defined as cardiac death and unplanned cardiovascular hospitalization. Cox hazard analysis was performed to identify parameters significantly associated with the outcomes. After excluding patients with non-ischemic cardiomyopathy diagnosed before and after undergoing CCT, coronary stenosis and previous revascularization, 57 patients had non-ischemic LIE and 408 showed no LIE. Compared with patients without LIE, non-ischemic LIE was significantly associated with increased high-sensitivity cardiac troponin T and B-type natriuretic peptide levels, left ventricular (LV) diastolic diameter, LV thickness, and impaired LV ejection fraction. The cumulative incidence of cardiovascular events was significantly higher in patients with non-ischemic LIE than in those without LIE (log-rank P=0.024). In the Cox multivariable analysis, non-ischemic LIE was associated with cardiovascular events (hazard ratio 7.01; 95% confidence interval 1.09–42.2; P=0.041).Conclusions: CCT may provide prognostic significance through the assessment of myocardial properties.
- Open Access
- 22 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (5) , 969-980
Does adding a delayed phase to cardiac computed tomography for coronary artery evaluation have prognostic value?
Aims: Cardiac computed tomography (CCT) assesses coronary anatomy and enables delayed-phase imaging, including extracellular volume fraction (ECV) for diffuse myocardial fibrosis and late iodine enhancement (LIE) for focal myocardial replacement fibrosis. ECV and LIE reflect distinct pathological processes; combining these measures may improve subclinical myocardial injury detection. This study evaluated LIE and ECV in patients undergoing CCT for coronary artery assessment and examined their association with clinical outcomes. The primary outcome was a composite of all-cause death and unplanned cardiovascular hospitalizations; the secondary outcome was cardiovascular events, defined as cardiac death and unplanned cardiovascular hospitalization. Methods and results: We analysed 1207 consecutive patients who underwent CCT between January 2020 and September 2022. Patients were categorized into four groups based on the presence of LIE and elevated ECV. Associations with LIE and ECV, individually and combined, were assessed using Cox proportional hazards models. Of 1305 patients, 1207 met inclusion criteria and were followed for a mean of 26.0 ± 19.1 months. Kaplan–Meier analysis demonstrated a stepwise increase in risk across the four groups, with those having LIE and elevated ECV showing the highest cumulative incidence of composite events (log-rank P = 0.027). This group had increased risk for the composite outcome [hazard ratio (HR) 1.84, 95% confidence interval (CI) 1.22–2.79] and cardiovascular events (HR 2.67, 95% CI 1.32–5.41). Conclusion: In patients undergoing CCT for coronary artery evaluation, coexistence of LIE and elevated ECV is associated with higher risk of cardiovascular events and their assessment may provide synergistic prognostic value.
- 22 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (5) , 969-980
Open AccessDoes adding a delayed phase to cardiac computed tomography for coronary artery evaluation have prognostic value?
Aims: Cardiac computed tomography (CCT) assesses coronary anatomy and enables delayed-phase imaging, including extracellular volume fraction (ECV) for diffuse myocardial fibrosis and late iodine enhancement (LIE) for focal myocardial replacement fibrosis. ECV and LIE reflect distinct pathological processes; combining these measures may improve subclinical myocardial injury detection. This study evaluated LIE and ECV in patients undergoing CCT for coronary artery assessment and examined their association with clinical outcomes. The primary outcome was a composite of all-cause death and unplanned cardiovascular hospitalizations; the secondary outcome was cardiovascular events, defined as cardiac death and unplanned cardiovascular hospitalization. Methods and results: We analysed 1207 consecutive patients who underwent CCT between January 2020 and September 2022. Patients were categorized into four groups based on the presence of LIE and elevated ECV. Associations with LIE and ECV, individually and combined, were assessed using Cox proportional hazards models. Of 1305 patients, 1207 met inclusion criteria and were followed for a mean of 26.0 ± 19.1 months. Kaplan–Meier analysis demonstrated a stepwise increase in risk across the four groups, with those having LIE and elevated ECV showing the highest cumulative incidence of composite events (log-rank P = 0.027). This group had increased risk for the composite outcome [hazard ratio (HR) 1.84, 95% confidence interval (CI) 1.22–2.79] and cardiovascular events (HR 2.67, 95% CI 1.32–5.41). Conclusion: In patients undergoing CCT for coronary artery evaluation, coexistence of LIE and elevated ECV is associated with higher risk of cardiovascular events and their assessment may provide synergistic prognostic value.
- Open Access
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e043736
Bio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study
Background: Bio‐ADM (bioactive adrenomedullin) is a vasoactive peptide hormone that predicts clinical outcomes in heart failure—the main driver of adverse outcomes in cardiac amyloidosis (CA). This prospective observational study sought to assess the prognostic role of bio‐ADM in CA. Methods: Patients with CA were enrolled from amyloid centers in Germany (observation cohort), Japan, and the United States (combined validation cohort). Bio‐ADM was quantified using the sphingotest bio‐ADM assay. Associations of bio‐ADM with all‐cause death and major adverse cardiovascular events over 2 years were assessed using Kaplan–Meier and Cox regression analyses. Likelihood ratio chi‐square tests for nested models evaluated whether adding bio‐ADM improves validated prognostic staging systems. Results: In both the German observation cohort (n=86) and the combined validation cohort from Japan and the United States (n=124), elevated bio‐ADM (>29 pg/mL) was associated with more frequent all‐cause death and major adverse cardiovascular events. Bio‐ADM remained independently associated with impaired overall ( P P 29 pg/mL) significantly improved the prognostic accuracy of the National Amyloidosis Centre (C‐index 0.674 to 0.787; P =0.002) and MayoATTR (C‐index 0.662 to 0.757; P <0.001) staging systems for cardiac transthyretin amyloidosis. Adding bio‐ADM to staging systems for cardiac immunoglobulin light chain amyloidosis yielded no significant changes. Conclusions: Bio‐ADM is a promising prognostic biomarker, especially in cardiac transthyretin amyloidosis, where it improved risk stratification when added to established staging systems. Further research is needed to clarify its role as part of staging systems for cardiac immunoglobulin light chain amyloidosis.
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e043736
Open AccessBio‐Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross‐Continental Multicenter Study
Background: Bio‐ADM (bioactive adrenomedullin) is a vasoactive peptide hormone that predicts clinical outcomes in heart failure—the main driver of adverse outcomes in cardiac amyloidosis (CA). This prospective observational study sought to assess the prognostic role of bio‐ADM in CA. Methods: Patients with CA were enrolled from amyloid centers in Germany (observation cohort), Japan, and the United States (combined validation cohort). Bio‐ADM was quantified using the sphingotest bio‐ADM assay. Associations of bio‐ADM with all‐cause death and major adverse cardiovascular events over 2 years were assessed using Kaplan–Meier and Cox regression analyses. Likelihood ratio chi‐square tests for nested models evaluated whether adding bio‐ADM improves validated prognostic staging systems. Results: In both the German observation cohort (n=86) and the combined validation cohort from Japan and the United States (n=124), elevated bio‐ADM (>29 pg/mL) was associated with more frequent all‐cause death and major adverse cardiovascular events. Bio‐ADM remained independently associated with impaired overall ( P P 29 pg/mL) significantly improved the prognostic accuracy of the National Amyloidosis Centre (C‐index 0.674 to 0.787; P =0.002) and MayoATTR (C‐index 0.662 to 0.757; P <0.001) staging systems for cardiac transthyretin amyloidosis. Adding bio‐ADM to staging systems for cardiac immunoglobulin light chain amyloidosis yielded no significant changes. Conclusions: Bio‐ADM is a promising prognostic biomarker, especially in cardiac transthyretin amyloidosis, where it improved risk stratification when added to established staging systems. Further research is needed to clarify its role as part of staging systems for cardiac immunoglobulin light chain amyloidosis.
- 29 November 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 87 (3) , 221-229
The impact of large v-waves of pulmonary artery wedge pressure in patients with wild-type transthyretin amyloid cardiomyopathy
- 29 November 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 87 (3) , 221-229
The impact of large v-waves of pulmonary artery wedge pressure in patients with wild-type transthyretin amyloid cardiomyopathy